Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. (Q53158182)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 February 2011

Language	Label	Description	Also known as
English	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.	scientific article published on 25 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Vladimir Semiglazov

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Kathleen I. Pritchard

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Aron Goldhirsch

6

object named as

Aron Goldhirsch

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

16

object named as

Anna Pluzanska

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Richard D Gelber

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Evandro Azambuja

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Susanne Muehlbauer

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Ian Smith

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

José Baselga

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Christian Jackisch

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

David Cameron

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Max Mano

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

José Luiz Pedrini

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Andrea Veronesi

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Cesar Mendiola

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Eduard Vrdoljak

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Michael J Eckart

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Zhenzhou Shen

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

George Skiadopoulos

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Marion Procter

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Martine J Piccart-Gebhart

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Richard Bell

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Herceptin Adjuvant (HERA) Trial Study Team

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Michael Untch

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

25 February 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

236-244

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu signal transduction in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Median follow-up in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970033-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70033-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21354370%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53158182&oldid=2124492836"